Morepen Laboratories Limited has successfully secured an unsecured term loan facility of ₹30 crores from Shinhan Bank, marking a significant financial milestone for the pharmaceutical company. The Finance Committee of the Board of Directors approved this credit facility during its meeting held on April 23, 2026, which commenced at 3:00 p.m. and concluded at 3:45 p.m.

Loan Facility Details

The comprehensive loan agreement encompasses several key financial parameters that demonstrate the structured approach to this funding arrangement:

Agreement Structure and Parties

The loan agreement involves Shinhan Bank as the lender and Morepen Laboratories Limited as the borrower. A notable aspect of this arrangement is the personal guarantee extended by Mr. Sushil Suri, who serves as the company's Promoter, Chairman & Managing Director. This personal guarantee provides additional security to the lender despite the unsecured nature of the term loan facility.

Financial Context and Outstanding Obligations

The company's existing financial obligations provide important context for this new facility. As disclosed in the regulatory filing, Morepen Laboratories' total outstanding loan exposure, excluding the present facility, stands at ₹182.62 crores (excluding vehicle loans and interest thereon). Additionally, the company currently maintains an outstanding amount of ₹20.45 crores with Shinhan Bank from previous arrangements.

Purpose and Business Application

The loan facility has been structured specifically for general business purposes, providing Morepen Laboratories with enhanced financial flexibility to support its operational requirements and strategic initiatives. The 36-month tenure with quarterly repayment structure offers a balanced approach to debt servicing while maintaining cash flow stability.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The agreement was executed on April 23, 2026, with all necessary documentation completed as per regulatory requirements.

Morepen Laboratories has successfully completed a United States Food and Drug Administration (USFDA) inspection at its Masulkhana facility in Himachal Pradesh, achieving zero observations and maintaining its track record of regulatory compliance. The company officially announced the inspection clearance through a regulatory filing to stock exchanges on April 17, 2026.

Official Announcement and Inspection Results

The pharmaceutical company announced that the USFDA inspection concluded with a Nil 483 status, indicating no regulatory observations or deficiencies were identified during the assessment. The inspection was successfully cleared on April 17, 2026, with the company formally notifying the National Stock Exchange of India and BSE Limited about the achievement through Company Secretary Vipul Kumar Srivastava.

Regulatory Compliance Excellence

This successful inspection represents Morepen Laboratories' fourth consecutive USFDA inspection without any observations over the past eight years, highlighting the company's consistent commitment to maintaining international pharmaceutical manufacturing standards. According to Executive Director Sanjay Suri, this achievement demonstrates the strength of the company's quality systems and team discipline in adhering to global standards, enhancing credibility with global regulators and paving the way for long-term supply contracts.

Strategic Market Position and Global Operations

The clean inspection status reinforces Morepen's position as a preferred partner for global pharmaceutical companies, successfully catering to regulated markets across the US, Europe, and other geographies. The company exports APIs to over 80 countries and maintains a strong presence in global supply chains, supported by regular customer audits and robust quality management systems aligned with current ICH and CFR guidelines.

Digital Transformation and Future Growth

Morepen continues to leverage its regulatory track record and technical expertise while strategically expanding into the Contract Development and Manufacturing Organization (CDMO) space. The company has invested significantly in digital systems, automation, and data integrity frameworks to ensure full compliance with global regulatory expectations and enhance operational efficiency across manufacturing processes.